Research of Natural Killer Cell (CD56+, CD16+, CD3-) and It's Activating Ligand (CD 112) in Acute Myeloid Leukemia
Marwa Abd Elstar Salama
Clinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Hossam Hodeib
Clinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Atef Mohamed Taha
Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Mohamed Kamal Zahrah
Clinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
*Author to whom correspondence should be addressed.
Abstract
Background: Myeloid, erythroid, megakaryocytic, and monocytic cell lineage progenitors are all involved in the development of acute myeloid leukemia (AML), making AML a highly diverse collection of leukemias. This research was aimed to evaluate the impact of natural killer cell (CD56+, CD16+, CD3-) and its activating receptor ligand (CD 112) on AML and their clinicopathological significance.
Methods: This prospective randomized research was carried out on 40 newly diagnosed AML, and 20 apparently healthy subjects age and sex matched to cases group. (Determination of natural killer cell and activating receptor ligand).
Results: There was an evident decrease in percentage of NK cells in newly diagnosed AML cases. There was an evident increase in expression of CD112 in newly diagnosed AML cases. An evidently higher OS in cases with low NK cells expression with cutoff ≤15.5.
Conclusions: There was an evident decrease in the level of NK cells and an evident increase in expression of CD112 in newly diagnosed AML cases. A lower percentage of NK cells and higher levels of expression of CD112 may predict better outcome of newly diagnosed AML cases.
Keywords: Natural killer cell, activating ligand (CD 112), acute myeloid leukemia